Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1828]
News [2772]
Articles [208]
Editorials [1]
Conferences [136]
elearning [13]
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
Comment: Dabrafenib plus trametinib significantly increases overall response...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )
6 Jun 2022
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )
6 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
COMy 2022: Multiple myeloma roundup
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
24 May 2022
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 May 2022
War in Ukraine: Impacts on the Ukrainian cancer care system
Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine
War in Ukraine: Impacts on the Ukrainian cancer care system ( Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine )
4 May 2022
War in Ukraine: Impacts on the Polish cancer care system and vaccination...
Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland
War in Ukraine: Impacts on the Polish cancer care system and vaccination challenges ( Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland )
4 May 2022
Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )
29 Apr 2022
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation